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E-cadherin relates to EGFR expression and lymph node metastasis in
primary breast carcinoma
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Summary Expression of the calcium-dependent cell-cell adhesion molecule E-cadherin has been examined in
187 primary breast carcinomas using an immunohistochemical technique. The pattern and extent of reactivity
has been correlated with clinicopathological data including tumour type, grade and lymph node status and with
other prognostic parameters including oestrogen receptor (ER) status, expression of c-erbB-2, pS2 protein and
epidermal growth factor receptor (EGFR). Two patterns of E-cadherin staining were observed in carcinomas,
membrane reactivity and a diffuse cytoplasmic staining. A marked difference in expression of E-cadherin was
observed between infiltrating lobular carcinomas (ILC) and infiltrating ductal carcinomas (IDC), the former
showing complete loss of membrane staining, whereas 93% of IDC retained some level of expression. In IDC
reactivity was not related to tumour grade but there was a significant association between reduced membrane
levels of E-cadherin and the presence oflymph node metastasis, and a highly significant correlation between the
presence of cytoplasmic E-cadherin and metastasis. A significant relationship was also demonstrated between
reduced E-cadherin reactivity and expression of EGFR. These findings emphasise the complexity of control of
E-cadherin in breast carcinomas and provide evidence of a link between membrane signalling pathways and
modulation of E-cadherin expression.
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Tumour cell invasion and metastasis is a multistep process
requiring complex alterations in adhesive interactions.
Detachment of tumour cells from the primary lesion is
considered to be an important early step in the metastatic
process (Coman, 1947). Adhesion is mediated by several
families of cell adhesion molecules, including integrins
(Hynes, 1992) and members of the immunoglobulin family
(Springer, 1990). However, in epithelial cells E-cadherin (also
known as L-CAM, uvomorulin and Arc-1) plays a critical
role in initiating and maintaining cell-cell contacts (Takeichi,
1988).
E-cadherin is a member of the growing family of calcium-
dependent cadherin adhesion molecules (Kemler, 1992). E-
cadherin molecules are located within adherens junctions and
are transmembrane structures mediating homotypic interac-
tions between one or more of the extracellular cadherin
repeats. The cytoplasmic region interacts with a group of
proteins named the catenins, which in turn are connected to
the actin microfilament network (Kemler, 1993).
That loss of E-cadherin function may be involved in
tumour cell invasion has been demonstrated by an inverse
relationship between expression of E-cadherin and invasive
behaviour in some tumour cell lines (Frixen et al., 1991), and
this tumour- suppressor function has been supported by
inhibition of tumour cell invasion following transfection of
cells with E-cadherin cDNA (Vleminckx et al., 1991). A more
complex relationship has been observed between unstable or
aberrant expression of cadherins and metastatic potential of
tumour cells (Hashimoto et al., 1989; Mareel et al., 1991).
While a clear role for E-cadherin in preventing tumour cell
invasion has emerged from these in vitro studies, the
relationship between E-cadherin expression in primary
tumours and other prognostic parameters is inconsistent. In
breast carcinomas, some studies have revealed a significant
correlation between reduced E-cadherin expression and the
presence of lymph node metastasis (Oka et al., 1993), and
with histological grade (Moll et al., 1993). However, other
studies have shown no such correlation (Lipponen et al.,
1994).
Evidence of the biological importance of E-cadherin in
breast carcinomas is illustrated by the studies of D'Souza et
al. (1994), who found that overexpression of erbB-2 in a non-
tumorigenic mammary epithelial cell line leads to down-
regulation of E-cadherin gene transcription. The erbB-2
proto-oncogene is a transmembrane tyrosine kinase receptor
that shows homology to epidermal growth factor receptor
(EGFR), and overexpression of this gene in breast
carcinomas is associated with a rapid growth rate and a
poor prognosis (Berger et al., 1988; Walker et al., 1989). That
it also affects E-cadherin gene transcription suggests that this
may be a mechanism whereby erbB-2 can affect the
metastatic process.
A further relationship between the regulation of cell
growth and E-cadherin expression is demonstrated by the
culture of MCF-7 tumour cells in the presence of the anti-
oestrogenic agent tamoxifen (Bracke et al., 1994). This agent,
which inhibits tumour cell growth, has been shown to restore
E-cadherin-mediated adhesive function to these cells. Control
of E-cadherin function can also be modulated by EGF.
Kemler (1993) showed that in vitro activation of the EGFR
with subsequent phosphorylation of its cytoplasmic domain is
associated with dissociation of the E-cadherin/catenin
complex from the cytoskeleton. Studies have shown that
expression of EGFR by breast carcinomas is related to a
poor prognosis (Sainsbury et al., 1987) and Kemler's (1993)
findings suggest that this may in part be mediated by altered
E-cadherin function. However, in contrast to this, Oka et al.
(1993) found a significant association between EGFR
expression in primary breast carcinomas and retained E-
cadherin reactivity.
Given this evidence of a relationship between E-cadherin
function and growth control, as well as invasive behaviour in
vitro, it is important to examine whether these associations
are maintained in an in vivo situation. The aim of this study,
therefore, was to examine the expression of E-cadherin in
primary breast carcinomas and to relate this to clinicopatho-
logical parameters including tumour grade and lymph node
status, and also to determine the relationship between E-
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cadherin reactivity and factors related to growth and poor
prognosis, such as c-erbB-2 and EGFR expression, and to
factors associated with less aggressive tumour behaviour such
as oestrogen receptor (ER) positivity and expression of the
oestrogen-regulated protein, pS2.
and grade, lymph node status in 154 cases, ER status in 161
cases, EGFR reactivity in 159 cases, c-erbB-2 expression in
110 cases and pS2 expression in 102 cases.
Statistics
For statistical analysis, the chi-squared test was used for
Materials and methods correlation with all pathological data.
Tissue specimens
Fresh tumour tissue was collected from patients undergoing
surgery between 1991 and 1994 and samples were immedi-
ately frozen in liquid nitrogen. Separate tissue was fixed in
formol saline and paraffin embedded for routine histopatho-
logical assessment. A total of 187 specimens were examined
including 156 infiltrating ductal carcinomas, 13 tubular
carcinomas, 12 infiltrating lobular carcinomas and six cases
of ductal carcinoma in situ (DCIS) with no invasive
component. Histological grading of the tumours was carried
out (RAW) using a modification of the Bloom and
Richardson method (Elston et al., 1991). Information on
lymph node status was known for 154 cases.
Immunohistochemistry
For detection of E-cadherin, 5 pm cryostat sections were cut
onto silane-coated slides and allowed to air dry for 30 min.
Sections were then fixed in acetone for 10 min at 4°C. The
sections were incubated in normal rabbit serum (Sigma) for
10 min to block non-specific binding and then incubated
overnight at 4°C with the mouse monoclonal anti-E-cadherin
antibody (Euro-Path Ltd) at a dilution of 1:50 in Tris-
buffered saline with 0.1% bovine serum albumin (BSA). A
standard streptavidin-biotin complex (ABC) indirect im-
munoperoxidase technique was used to localise the bound
antibody, which involved sequential incubation with biotiny-
lated rabbit anti-mouse IgG at a dilution of 1:200 and
streptavidin combined in vitro with biotinylated horseradish
peroxidase (Dako), the reaction product being visualised
using diaminobenzidine (DAB) hydrochloride.
Known positive cases (benign breast tissue) and negative
controls (omission of the primary antibody) were included in
each run and were shown to be positive and negative
respectively. Normal breast epithelial elements in the tumour
sections were used as internal positive controls.
Frozen tissue was also used for detection of oestrogen
receptor (ER), using the ERICA Kit (Abbott), and for
detection of EGFR, using EGFR1 monoclonal antibody
(Amersham) at a dilution of 1:50. Formalin-fixed, paraffin-
embedded tissue was used for detection of c-erbB-2, using the
monoclonal antibody NCL-CBI1 (Novocastra) at a dilution
of 1:100, and for localisation of pS2 protein using the
monoclonal antibody Histo CIS pS2 undiluted. In each case a
standard ABC technique was used as described above.
Known positive cases and negative controls were included
in each run.
Evaluation
The extent and distribution of reactivity for E-cadherin was
recorded in each case using a semi-quantitive scoring system.
Staining was classed as 4 if >80% of the tumour showed
reactivity, 3 if 50-80% was positive, 2 if 20-50% of the
tumour showed staining, 1 for patchy, focal reactivity and 0
if there was no evidence of staining. This system was applied
to each tumour to determine the extent of reactivity for each
of the two patterns of localisation observed, membrane and
cytoplasmic.
Tumours were recorded as ER positive if > 10% of the
tumour cells showed staining and, similarly, sections stained
for pS2 were considered positive if > 10% of the tumour was
staining. Reactivity for c-erbB-2 and EGFR was also
recorded.
E-cadherin expression was compared with tumour type
Results
E-cadherin reactivity in relation to clinicopathological data
Cases of normal and benign breast tissue (fibrocystic change
and fibroadenoma) were used as positive controls for E-
cadherin reactivity. These demonstrated strong membrane
staining of the glandular epithelial cells with localisation at
the intercellular borders (Figure 1). Non-epithelial cells did
not express E-cadherin. Normal breast epithelial elements
within tumour sections displayed similar strong reactivity.
In contrast to normal breast tissue, two patterns of
staining for E-cadherin were observed in carcinomas, with
reactivity either localised at the cell membrane in a similar
manner to that seen in normal and benign epithelium, or
distributed diffusely within the cytoplasm, a pattern not
observed in non-malignant epithelium. Of the 156 infiltrating
ductal carcinomas (IDC), nine showed no evidence of
staining for E-cadherin, either membrane or cytoplasmic.
The remaining 147 IDC showed variable levels of membrane
staining for E-cadherin, although in no case was this as
strong as the level of reactivity observed in normal glandular
elements (Figure 2). In addition to membrane staining, in
many of the tumours a variable proportion of cells exhibited
cytoplasmic reactivity for E-cadherin, in some cases this
being the predominant pattern observed (Figure 3). Of the 13
cases of tubular carcinoma examined, one showed no
reactivity for E-cadherin, either membrane or cytoplasmic,
despite a normal distribution of E-cadherin in adjacent non-
malignant ducts. The other tubular carcinomas displayed
variable levels of membrane and cytoplasmic staining in a
pattern similar to that of the IDC.
In marked contrast to the IDC, none of the 12 cases of
infiltrating lobular carcinomas included in the study showed
any evidence of membrane reactivity for E-cadherin (Figure
4), although in three cases there was weak cytoplasmic
reactivity in a small proportion of the tumour cells. Three of
the cases also contained areas of lobular carcinoma in situ
(LCIS), which were similarly negative for E-cadherin.
The six cases of pure DCIS, including one case ofcomedo-
Figure 1 Section of normal breast tissue showing strong
membrane staining for E-cadherin in epithelial cells. There is no
staining of non-epithelial elements.E-cadherin in breast cancer
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type DCIS, all exhibited normal or near normal membrane
expression of E-cadherin. No significant cytoplasmic reactiv-
ity was observed.
The extent and pattern of staining for E-cadherin was
compared with the tumour grade of the IDC. Of the 156
cases, 24 were histological grade I, 61 grade II and 71 grade
III. While there was a trend towards the better differentiated
tumours retaining membrane reactivity for E-cadherin, this
did not reach statistical significance. There was no relation-
ship between tumour grade and the presence of cytoplasmic
E-cadherin (Table I). The absence of reactivity observed in
nine IDC was also not related to tumour grade. The 13
tubular carcinomas, all by definition grade I, displayed
variable levels and patterns of staining, some having
predominantly cytoplasmic reactivity, others with near
normal levels of membrane staining.
When the pattern of E-cadherin expression was correlated
with the lymph node status of the patient, both for the IDC
alone and the IDC together with the tubular carcinomas,
there was a significant association between reduced
membrane reactivity and the presence of lymph node
metastasis (0.005>P>0.001). Interestingly, a highly signifi-
cant association was demonstrated between the presence of
cytoplasmic reactivity for E-cadherin in the tumour cells and
Figure 2 Moderately differentiated infiltrating ductal carcinoma
displaying membrane reactivity for E-cadherin on the majority of
tumour cells.
lymph node metastasis (P<0.001) (Table I), including two
unusual cases of tubular carcinoma which showed extensive
cytoplasmic reactivity. The lack of membrane E-cadherin in
the infiltrating lobular carcinomas did not relate to lymph
node metastasis, with eight cases being lymph node-positive
and two being lymph node-negative. Similarly, there was no
relationship to the presence of cytoplasmic reactivity.
E-cadherin reactivity in relation to other markers
For the infiltrating ductal carcinomas, no significant
correlation was observed between the extent and pattern of
E-cadherin reactivity and ER status, c-erbB-2 expression or
pS2 expression (Table I). However, a statistically significant
relationship was evident between the presence of cytoplasmic
reactivity for E-cadherin in the tumour cells and EGFR
positivity (0.01>P>0.005). This relationship could also be
demonstrated at the cellular level, with colocalisation of the
cytoplasmic E-cadherin and EGFR within tumour groups.
No such relationship was seen for the presence of membrane
reactivity and EGFR positivity. These relationships were
maintained when the tubular carcinomas were included in
this group.
The groups of infiltrating lobular carcinoma and DCIS
were too small for statistical analysis. However, no clear
relationship with any of the factors was evident.
Discussion
The process of tumour progression, invasion and metastasis
is a complex cascade of events (Hart et al., 1989), which
involves escape from normal growth control mechanisms,
invasion of surrounding stroma and release of neoplastic cells
from the primary tumour with subsequent establishment and
growth at a distant site. Many of these processes imply
altered adhesive function of the neoplastic cells, and in
epithelial tumours, altered E-cadherin function has been
shown to play a critical role in allowing release of neoplastic
cells from a normal cohesive structure. However, there is
recent evidence that different stages of tumour development
may be closely linked, with mitogenic signals also affecting
cell adhesion (D'Souza et al., 1994), and this study has
evaluated whether these relationships are maintained in vivo.
A number of studies have established an inverse
correlation between E-cadherin expression and tumour
differentiation (Schipper et al., 1991; Kinsella et al., 1993).
In infiltrating ductal carcinomas (IDC) of the breast, the
relationship of E-cadherin expression to clinicopathological
Figure 3 A moderately differentiated infiltrating ductal carcino- Figure 4 Absence of reactivity for E-cadherin in an infiltrating
ma displaying predominantly diffuse cytoplasmic reactivity for E- lobular carcinoma (T). The adjacent normal duct (N) displays
cadherin in the tumour cells. strong membrane staining.
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Table I Correlation of E-cadherin reactivity in infiltrating ductal carcinomas and tubular carcinomas with clinicopathological features and
other markers
Mem<50% Mem>50% P-value Cyt<50% Cyt>50% P-value
Grade I 51% (n=19) 49% (n=18) 54% (n=20) 46% (n=17)
Grade II 70% (n=43) 30% (n=18) X2=5.09 61% (n=37) 39% (n=24) X2=3.25
Grade III 72% (n=51) 28% (n=20) NS 45% (n=32) 55% (n=39) NS
LN positive 78% (n=57) 22% (n= 16) x2=9.43 26% (n= 19) 74% (n=54) x2=39.3
LN negative 56% (n=45) 44% (n=36) 0.005>P>0.001 77% (n=62) 23% (n= 19) <0.001
c-erbB-2+ 64% (n= 18) 36% (n= 10) X2= 1.6 43% (n= 12) 57% (n= 16) X2=0.57
c-erbB-2- 77% (n=63) 23% (n=19) NS 51% (n=42) 49% (n=40) NS
EGFR+ 72% (n=28) 28% (n=ll) X2=0.76 36% (n=14) 64% (n=25) 2=6.696
EGFR- 64% (n=77) 36% (n=43) NS 59% (n=71) 41% (n=49) 0.01>P>0.005
ER+ 63% (n=69) 37% (n=40) x2=1.13 54% (n=59) 46% (n=50) 2=0.001
ER- 71% (n=37) 29% (n= 15) NS 54% (n=28) 46% (n=42) NS
pS2+ 69% (n=50) 31% (n=22) x2=0 50% (n=36) 50% (n=36) x2=0.38
pS2- 67% (n=8) 33% (n=4) NS 42% (n=5) 58% (n=7) NS
Mem, membrane staining; cyt, cytoplasmic staining; LN, lymph node; NS, not significant.
parameters is inconsistent. Moll et al. (1993) and Oka et al.
(1993) found that reduced E-cadherin related to poor
differentiation. The latter group also demonstrated a
significant association between reduced E-cadherin staining
and the presence of lymph node metastasis. In contrast to
this, Lipponen et al. (1994) examined 179 IDC and found no
correlation with tumour grade or lymph node status. In our
study 146/156 (93%) of IDC showed some evidence of
staining, but, while there was a trend towards grade I IDC
retaining E-cadherin expression, there was no statistically
significant relationship between the extent or pattern of
reactivity to tumour grade. However, in keeping with the
observations of Oka et al. (1993), there was a significant
correlation between reduced membrane staining for E-
cadherin and a positive lymph node status. The presence of
diffuse cytoplasmic reactivity for E-cadherin has previously
been reported in certain tumours (Pignatelli et al., 1994),
although the significance of this distribution has not been
addressed. We demonstrated a highly significant association
between tumour cytoplasmic reactivity for E-cadherin and
the presence of lymph node metastasis. There are a number
of possible explanations for this finding. One is that the
cytoplasmic reactivity indicates a reversible change in E-
cadherin expression by the cell in response to the local
environment. It has been demonstrated that E-cadherin
expression can easily be altered in vitro in response to the
culture environment (Mareel et al., 1991) and that highly
metastatic ovarian tumour cells have unstable E-cadherin
expression (Hashimoto et al., 1989). Such a temporal
disruption of E-cadherin-mediated adhesion would allow
tumour cell detachment, while re-expression could favour
colonisation at a distant site. In support of this, there are
reports of increased E-cadherin expression in metastatic
lesions compared with their primary tumour (Mayer et al.,
1993).
Alternatively, such aberrant E-cadherin localisation may
be the result of abnormal catenin expression. Incorporation
of E-cadherin into stable cell-cell contacts is modulated by
the cytoplasmic proteins, a-, f-and y-catenin (Hirano et al.,
1992; Hinck et al., 1994). Thus, loss of one or more of the
catenin proteins may be expected to result in weak
association of E-cadherin to the cytoskeleton, distribution
diffusely within the cytoplasm and loss of adhesive function.
Interestingly, altered expression of y-catenin (plakoglobin)
has recently been reported in human breast cancer cells
(Sommers et al., 1994). It would be of interest to examine the
association of cytoplasmic reactivity for E-cadherin with
catenin gene expression.
There is increasing evidence that E-cadherin function may
be modulated by growth factor activity. Hoschuetzky et al.
(1994) have demonstrated the physical association of EGFR
with E-cadherin via fl-catenin, while Shiozaki et al. (1995)
have shown that phosphorylation of EGFR leads to
dissociation of E-cadherin/catenin complexes from the
cytoskeleton. In keeping with this, our study demonstrates
a significant correlation between the expression of EGFR by
tumour cells and the presence of cytoplasmic reactivity for E-
cadherin. This may illustrate one mechanism whereby local
environmental influences could modulate both tumour cell
growth and invasive behaviour. Oka et al. (1993) have
reported an association between EGFR positivity and
retained E-cadherin expression by tumours, although the
localisation of this reactivity was not reported.
Further evidence linking cadherins to signalling pathways
is illustrated by the down-regulation of E-cadherin transcrip-
tion in response to overexpression of the tyrosine kinase
receptor erbB-2 in a non-tumorigenic human mammary
epithelial cell line (D'Souza et al., 1994). Our study showed
no relationship between c-erbB-2 expression and E-cadherin
reactivity, demonstrating perhaps the complexity of factors
involved in tumour progression.
Possession of ER and reactivity for the oestrogen-
regulated protein, pS2, are generally indicative of tumours
with a good prognosis (Foekens et al., 1990). Transfection of
a mouse mammary adenocarcinoma cell line with pS2 cDNA
has been shown to alter cell phenotype, giving the previously
cohesive cell colonies a more dispersed structure (Williams et
al., 1995) and suggesting altered adhesive interactions,
although our study does not support a direct effect on E-
cadherin expression. In contrast to Lipponen et al. (1994), we
found no correlation between E-cadherin expression and ER
status.
While E-cadherin reactivity was maintained in 93% of
infiltrating ductal carcinomas, none of the infiltrating lobular
carcinomas or LCIS showed evidence of membrane E-
cadherin. These findings are in keeping with those of other
workers (Moll et al., 1993; Lipponen et al., 1994) and suggest
distinct modes of invasion in these two cancer types.
Interestingly, a similar pattern of staining is seen in diffuse-
type gastric carcinomas, which are also characterised by lack
of glandular differentiation and single, non-polarised cells
infiltrating stroma (Mayer et al., 1993). Furthermore,
mutations in the E-cadherin gene have been discovered in
this form of gastric carcinoma (Becker et al., 1994). In
infiltrating lobular carcinoma of breast also, loss of mRNA
for E-cadherin has been demonstrated (Rasbridge et al.,
1995), and in some cases gene mutations have been identified
(Kanai et al., 1994; Berx et al., 1995).
In conclusion, the role of E-cadherin in breast tumour
progression appears increasingly complex. Whereas in ILC
loss of E-cadherin appears to be an early event in tumour
development, in IDC altered E-cadherin expression appears
to be more directly related to the metastatic process. The
association of cytoplasmic E-cadherin with lymph nodeE-cadmeb inbrsag cance
I Jones et i
1241
metastasis suggests a sophisticated control over cell-cell
adhesion possibly in response to local growth factors such as
EGF. This link between E-adherin expression and signalling
pathways may be an important stage in understanding
tumour progression and examination of the dynamic
interaction between these two factors, in particular the
control of catenin expression in relation to this, merits
further study.
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